- Home
- CRSP vs ASO Comparison
CRSP vs ASO Comparison
Compare CRSP & ASO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- ASO
- Stock Information
- Founded
- CRSP 2013
- ASO 1938
- Country
- CRSP Switzerland
- ASO United States
- Employees
- CRSP N/A
- ASO N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- ASO Recreational Games/Products/Toys
- Sector
- CRSP Health Care
- ASO Consumer Discretionary
- Exchange
- CRSP Nasdaq
- ASO Nasdaq
- Market Cap
- CRSP 4.3B
- ASO 3.5B
- IPO Year
- CRSP 2016
- ASO 2020
- Fundamental
- Price
- CRSP $43.65
- ASO $58.11
- Analyst Decision
- CRSP Buy
- ASO Buy
- Analyst Count
- CRSP 18
- ASO 17
- Target Price
- CRSP $76.60
- ASO $63.53
- AVG Volume (30 Days)
- CRSP 1.8M
- ASO 1.9M
- Earning Date
- CRSP 11-05-2024
- ASO 12-10-2024
- Dividend Yield
- CRSP N/A
- ASO 0.78%
- EPS Growth
- CRSP N/A
- ASO N/A
- EPS
- CRSP N/A
- ASO 6.08
- Revenue
- CRSP $202,829,000.00
- ASO $6,051,358,000.00
- Revenue This Year
- CRSP N/A
- ASO N/A
- Revenue Next Year
- CRSP $758.18
- ASO $5.99
- P/E Ratio
- CRSP N/A
- ASO $9.21
- Revenue Growth
- CRSP 19.31
- ASO N/A
- 52 Week Low
- CRSP $42.86
- ASO $44.73
- 52 Week High
- CRSP $91.10
- ASO $75.73
- Technical
- Relative Strength Index (RSI)
- CRSP 39.11
- ASO 68.17
- Support Level
- CRSP $43.40
- ASO $53.53
- Resistance Level
- CRSP $53.97
- ASO $56.15
- Average True Range (ATR)
- CRSP 2.37
- ASO 2.17
- MACD
- CRSP -0.78
- ASO 0.86
- Stochastic Oscillator
- CRSP 9.53
- ASO 90.11
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About ASO Academy Sports and Outdoors Inc.
Academy Sports and Outdoors Inc is engaged in the retail business of sporting goods and outdoor recreation products. The product categories of the company are outdoors, apparel, sports & recreation, and footwear.